image: To illustrate how generative AI breakthrough is driving real-world healthcare solutions, Alex Zhavoronkov PhD, founder and CEO of Insilico Medicine, will be speaking about the topic “Can Cell-Based lnnovation Keep Humanity in Peak Condition?” from 1:45 PM-2:10 PM local time, Oct 29. The next day, Alex Aliper, PhD, President of Insilico Medicine, will share the know-hows obtained in continued AI platform development and reproducible proof-of-concept achieved with highly efficient novel pipelines at Insilico, in the FII Innovators Pitch 2025 session.
Credit: Insilico Medicine & FII9
From October 27-30, 2025, The 9th Edition of the Future Investment Initiative (FII9) will gather more than 600 distinguished speakers and 20 confirmed Heads of State at KAICC, Riyadh, Saudi Arabia, for cutting-edge discussions on investment, innovation, and global progress.
To illustrate how generative AI breakthrough is driving real-world healthcare solutions, Alex Zhavoronkov PhD, founder and CEO of Insilico Medicine, will be speaking about the topic “Can Cell-Based lnnovation Keep Humanity in Peak Condition?” from 1:45 PM-2:10 PM local time, Oct 29. The next day, Alex Aliper, PhD, President of Insilico Medicine, will share the know-hows obtained in continued AI platform development and reproducible proof-of-concept achieved with highly efficient novel pipelines at Insilico, in the FII Innovators Pitch 2025 session.
Under the theme “The Key to Prosperity,” FII9 focuses on urgent topics including global growth, AI and technology responsibility, as well as the next generation of talent, fostering communication between global investors, visionary leaders, and pioneering minds as the world’s leading platform for dialogue and action.
After first describing the concept of using generative AI for the design of novel molecules in a peer-reviewed journal in 2016, Insilico has proceeded to the exploration into “Pharmaceutical Superintelligence”, aspiring for a future where AI platforms enable autonomous drug discovery without relying on human guidance. To dive deeper into the innovative concept, please refer to two recent preprint papers focusing on TargetPro and Target Benchmark, Insilico’s biology superintelligence system for de-risking and pipeline prioritization, and LEGION, a powerful AI-driven workflow for systematic chemical space exploration.
Since founding in 2014, Insilico has published over 200 peer-reviewed papers. Leveraging sustained scientific breakthroughs at the intersection of biotechnology, artificial intelligence, and automation, Insilico ranked Top 100 global corporate institutions in Nature Index's "2025 Research Leaders: global corporate institutions for biological sciences and natural sciences publications".
By integrating the technologies of AI and automation, Insilico has demonstrated significant efficiency boost compared to traditional drug discovery methods (often requiring 2.5-4 years), as announced in the recent key timeline benchmarks for internal DC programs from 2021 to 2024: the average time to DC is 12-18 months, with 60-200 molecules synthesized and tested per program.
About Insilico Medicine
Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico is extending the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.
For more information, please visit www.insilico.com.